WAVE Life Sciences (WVE)
(Delayed Data from NSDQ)
$13.51 USD
+0.32 (2.43%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $13.20 -0.31 (-2.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
WVE 13.51 +0.32(2.43%)
Will WVE be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for WVE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for WVE
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates
Novavax to Report Q3 Earnings: Here's What to Expect
WVE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know
What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now?
Other News for WVE
PepGen stock down 22% on FDA clinical hold (update)
PepGen stock craters 35% on FDA clinical hold
WAVE Life Sciences Ltd (WVE) to Present at J.P. Morgan Healthcare Conference
Promising Pipeline Advancements and Investor Confidence Justify Buy Rating for Wave Life Sciences
Buy Rating for Wave Life Sciences: Favorable Regulatory Environment and Promising WVE-003 Data